CD274 and non-small cell lung carcinoma: Multiple studies have proved that patients with driver-gene-negative advanced NSCLC with programmed death ligand-1 (PD-L1) ≥ 50% using single-agent immunotherapy have a significantly better outcome than standard CT [2,3,4,5].